haematology
Blood cancers

Continuous therapy in multiple myeloma: it’s about time

Sponsored by Celgene Pty Ltd

On the 1 February 2017, Australia joined the US and Europe in making continuous therapy with Revlimid (lenalidomide) plus dexamethasone reimbursed on the Pharmaceutical Benefits Scheme for newly diagnosed transplant ineligible patients with multiple myeloma1. This is exciting news, and the limbic spoke with Dr Hang Quach, Consultant Haematologist at St Vincent’s Hospital, Melbourne, and ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic